{
  "slug": "shingles-vaccination-dementia",
  "round": 2,
  "group": 7,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "canonical_path": "hsef_v53_traffic_ranks_16_20_2026-10-13/shingles-vaccination-dementia/shingles-vaccination-dementia.review.md",
  "level_before": "Δ",
  "level_after": "Δ",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "role_before": "reinforcing / stabilizing factor",
  "role_after": "reinforcing / stabilizing factor",
  "pmids_checked": 53,
  "pmids_failed": 0,
  "retractions_or_eoc_found": 0,
  "claims_spot_checked": 12,
  "validator": {
    "before": "FAIL — 1 fail, 0 warn, 33 pass (v5.lay_summary)",
    "after": "FAIL — 1 fail, 0 warn, 33 pass (v5.lay_summary)",
    "note": "Validator 2.4 enforces the v5.4 lay-summary requirement against a v5.3 package; unchanged by this pass."
  },
  "findings": [
    {
      "id": "AR-1",
      "severity": "Major",
      "type": "rendering_defect",
      "location": [
        "prose review, throughout (100 tokens)",
        "score card, throughout (228 tokens)"
      ],
      "original": "numeral-adjacent space loss affecting grade-bearing statistics, e.g. effect3.5percentage / diagnosis1.8points / with95%CI0.0-54.7 / despite57covariates / not17%risk / age80 / uptake16.4points; dropped leading zeros in HRs.89/.68, CI-.40to.27, RD-.06; 38 bare reference numbers fused to the preceding word",
      "corrected": "spaces restored, leading zeros restored to match the cited sources, PMID prefix restored on the fused reference numbers",
      "evidence": "Known 'randomize3808' defect class, here degrading statistics rather than only prose, which is why it is rated Major. Identifier tokens (PMID, PMC, NCT, DOI, study_id, receipt handles, version strings, hashes, URLs, AS01/HSV/HbA1c) were guarded and verified unchanged; a whitespace-insensitive comparison confirms no other wording or number changed."
    },
    {
      "id": "AR-2",
      "severity": "Minor",
      "type": "missing_required_artifact",
      "location": [
        "Final score, causal direction and M/S/D, Divergence line",
        "scorecard extended_scoring_MSD.divergence.justification"
      ],
      "original": "Divergence: Contested. No manufactured field consensus or arithmetic gap.",
      "corrected": "Same value, now naming the two conflicting framings (the Welsh/Australian/Canadian eligibility analyses presented as near-settled prevention versus the 2026 quantitative critique and the unreviewed English null) that make a single implied level indefensible.",
      "evidence": "Divergence requires a checkable artifact; both the prose and the score card asserted only its absence."
    },
    {
      "id": "AR-3",
      "severity": "Editorial",
      "type": "editorial",
      "location": [
        "same Divergence fields"
      ],
      "original": "n/a",
      "corrected": "original disclaimer retained alongside the added artifact",
      "evidence": "Preserves the author's qualification rather than replacing it."
    },
    {
      "id": "AR-4",
      "severity": "Major",
      "type": "renderer_defect_nominal_as_rival",
      "location": [
        "AT A GLANCE, Best-supported rival line"
      ],
      "original": "Local vaccine effect on dementia diagnosis (the nominal, tournament rank 1)",
      "corrected": "Health selection and ascertainment (rank 2), with a clause noting the nominal ranks first and so is not its own rival",
      "evidence": "Renderer defect: the \"Best-supported rival\" line is generated from `competing_models.models_evaluated[0]`, which here carries `is_nominal: true` and rank 1, so the prose named the nominal as its own rival. Prose-only; the tournament, the level and Rule 9 are untouched. The paragraph body already argued that the Welsh design is the strongest separator against ordinary healthy-user selection, which is the rank-2 rival."
    },
    {
      "id": "AR-5",
      "severity": "Minor",
      "type": "confidence_rationale",
      "location": [
        "scorecard final_score.confidence_rationale"
      ],
      "original": "density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "corrected": "evidence density, independent replication and heterogeneity of controls set the confidence; access depth and belief in correctness do not.",
      "evidence": "The framework ties confidence to evidence density and reproducibility; the boilerplate rationale named \"incomplete access\" as a determinant. Rewritten to rest on density, replication and heterogeneity. Band re-tested against both band texts and unchanged. Moderate remains correct under the framework's Moderate text."
    }
  ],
  "rejected_findings": [
    {
      "id": "RJ-1",
      "claim": "The headline should fall to Beta given the 2026 quantitative critique (implied effectiveness of 177%, 84% and 111% outside Wales, no population-level dementia decline) and the unreviewed English null analysis.",
      "resolution": "Rejected. The framework names natural experiments as a field-valid equivalent where deliberate human perturbation is unavailable, and Delta requires one such perturbation with a positive phenotype-relevant result. The Welsh first stage runs from 0.01% to 47.2% across one week of birth date with balanced covariates and placebo cutoffs; the critique attacks magnitude and cross-country coherence rather than that local design, and the English analysis is a preprint the review already excludes from its count. Epsilon was also rejected because the sex boundary rests on a non-significant interaction, so no causal failure context is mapped. Most contestable judgement in the review."
    },
    {
      "id": "RJ-2",
      "claim": "Aggregation misapplied.",
      "resolution": "Rejected. Primary-subclaim pre-registered with SC2 named; alternatives reported (weakest-link Beta, scope-matched Delta); no Epsilon subclaim involved."
    },
    {
      "id": "RJ-3",
      "claim": "Collective-author leading-comma defect present.",
      "resolution": "Rejected. Reference 50 renders correctly as 'SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM et al.' with no leading comma and no dropped author."
    },
    {
      "id": "RJ-4",
      "claim": "Four reference years disagree with PubMed.",
      "resolution": "Rejected; refs [4], [12], [33], [49] differ by one year, print versus e-pub."
    },
    {
      "id": "RJ-5",
      "claim": "Momentum artifact is boilerplate.",
      "resolution": "Rejected. 'Mechanistic only' is the correct value and the artifact names a trial type rather than a single study; thin but compliant and at a non-modal value."
    },
    {
      "id": "RJ-6",
      "claim": "Empty DOI fields, retrieval handles or 'PMID not supplied' strings present.",
      "resolution": "Rejected; screened and none present."
    },
    {
      "id": "RJ-7",
      "claim": "Lead-reported artifacts: false approval boilerplate, reviewer-notes contradiction, confidence band wrong.",
      "resolution": "Screened. The first two do not apply (not a revised edition, no provenance clause of that kind). The band was re-tested against both framework texts and Moderate stands."
    }
  ],
  "numeric_audit": {
    "absolute_vs_relative_errors": 0,
    "population_errors": 0,
    "citation_inversions": 0,
    "checked": [
      "40175543 Welsh receipt effect 3.5 percentage points over 7 years (source also gives 20.0% relative; review uses the absolute figure)",
      "40175543 first stage 0.01% to 47.2% uptake across one week of birth date",
      "40267506 Australian uptake +16.4 points, dementia -1.8 points over 7.4 years, labelled an eligibility effect",
      "41579903 Canadian clinical effect about 2.0 percentage points over 5.5 years; uptake from a separate survey",
      "39053634 17% more diagnosis-free time and 164 additional days in those subsequently affected, stated twice as not a 17% risk reduction",
      "39733478 Optum HR 0.89 one dose, 0.68 two doses; antivirals protective",
      "42296498 509,926 entrants, 1.73% vaccinated, 87.0% after discharge, 57 covariates, negative controls indicating residual confounding",
      "40562756 AS01 shingles and RSV vaccines, 18-month risk, no between-product difference; source's adjuvant-necessity inference refused",
      "40258956 326 villages, 33,995 participants, all-cause dementia risk ratio 0.85 over 48 months",
      "42754179 implied effectiveness 18% Wales, 177% Australia, 84% and 111% Canada",
      "English medRxiv preprint recorded as unreviewed and excluded from the primary count",
      "review's own statement that eligibility effect, receipt CACE, risk reduction and diagnosis-free time are different quantities"
    ]
  },
  "residual_limitations": "The Welsh analysis frame of 282,541 participants, the Canadian first-stage estimates of 27.4 and 13.9 percentage points, and the sex-interaction p value of .218 are Methods- or Results-level figures, confirmable in this pass only against the review's own partial-body receipts rather than independently.",
  "propagation_strings_for_lead": [
    {
      "file_class": "package-level renderings of this review's prose or numbers",
      "old": "any AR-1 fused token (e.g. 'effect3.5percentage', 'HRs.89/.68', 'not17%risk')",
      "new": "re-render from the corrected review rather than patching individual tokens",
      "scope": "100 tokens in the review and 228 in the score card"
    },
    {
      "file_class": "package-level (OVERVIEW.md, READER.html, EDITORIAL_HANDOFF.md)",
      "old": "Best-supported rival: Local vaccine effect on dementia diagnosis",
      "new": "Best-supported rival: Health selection and ascertainment (rank 2)",
      "scope": "the shingles-vaccination-dementia best-supported-rival field only"
    }
  ],
  "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14.",
  "findings_major": 2,
  "findings_minor": 2,
  "findings_editorial": 1,
  "rejected_count": 7,
  "lead_reported_artifacts_checked": [
    "false approval boilerplate (revised editions only)",
    "confidence band set from access depth",
    "renderer bug printing the nominal as best-supported rival",
    "reviewer-notes / provenance contradiction"
  ],
  "lead_policy_confidence_band": {
    "recorded": "2026-10-14, lead adjudication",
    "step_1": "Strike access depth as a confidence determinant everywhere; it is neither evidence density nor reproducibility and never justifies a band.",
    "step_2": "Re-derive the band from what remains. Raise it only if access depth was the sole reason holding it down and the cited evidence meets the High text. Substantive evidence-quality or reproducibility concerns documented in the review (indirect effects, incomplete washout, residual confounding of the mechanism, reporter rather than endogenous readouts) are valid determinants and the band stands.",
    "principle": "A reviewer's uncertainty about the evidence is a legitimate reason for Moderate; a reviewer's uncertainty about their own reading access is not.",
    "precedents": "hiv-aids raised Moderate to High (invalid reason and nothing else); 3d-genome-regulation stays Moderate (real scientific reservations recorded in its own text). The two are consistent.",
    "reviewer_position": "Agreed; this is the distinction applied in this pass.",
    "applied_here": "Step 1 applied (rationale rewritten under AR-5). Step 2: band stands at Moderate on valid determinants — the causal core is a small family of eligibility natural experiments with an unresolved published quantitative challenge, which is not extensive, well-established replication."
  }
}